The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER).
 
Andrew Wagner
Honoraria - AADi; Cogent Biosciences
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; EMD Serono/Merck; InhibRx; Pharmaessentia; SERVIER
Research Funding - AADi (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Rain Therapeutics (Inst); Sumitomo Pharma Oncology (Inst)
 
Silvia Stacchiotti
Honoraria - Boehringer Ingelheim; Gentili; GlaxoSmithKline; PharmaMar; Servier
Consulting or Advisory Role - Agenus; Bayer; Boehringer Ingelheim; Daiichi Sankyo; deciphera; GlaxoSmithKline; Ikena Oncology; Ipsen; NEC OncoImmunity AS; Pharmaessentia; Regeneron; SERVIER
Research Funding - Abbisko Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Channa Debruyne
Employment - SERVIER
 
Abdulazeez Salawu
Honoraria - Bayer; Medison
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Knight Therapeutics; Medison; Taiho Pharmaceutical
Research Funding - Amgen; EMD Serono; PTC Therapeutics; SERVIER; Torl Biotherapeutics
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Fernando Campos
Consulting or Advisory Role - Ache Company
Research Funding - Novartis
 
Hiroaki Hiraga
Consulting or Advisory Role - Nippon Boehringer Ingelheim
Speakers' Bureau - Bayer; Chugai Pharma; Eisai; Kyowa Kirin International; Taiho Pharmaceutical
Research Funding - Nippon Boehringer Ingelheim (Inst); Taiho Pharmaceutical (Inst)
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Akira Kawai
Honoraria - Boehringer Ingelheim; Taiho Pharmaceutical
 
Ganessan Kichenadasse
No Relationships to Disclose
 
Yoshihiro Nishida
Honoraria - Alexion Pharmaceuticals; Asahi Kasei; Astellas Pharma; Chugai Pharma; Daiichi Sankyo; Eisai; Hisamitsu Pharmaceutical; Kaken Pharmaceutical; Kyowa Hakko Kirin Co., Ltd.; Lilly Japan; Ono Pharmaceutical
Consulting or Advisory Role - Alexion Pharmaceuticals; Boehringer Ingelheim; Daiichi Sankyo; Seikagaku
Research Funding - Alexion Pharmaceuticals; Boehringer Ingelheim; daiichi Sankyo; Kuraray
 
Seth Pollack
Consulting or Advisory Role - AADi; Apexigen; Bayer; Daiichi Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Obsidian Therapeutics; Sensei Biotherapeutics; T-knife Therapeutics
Speakers' Bureau - Deciphera
Research Funding - Obsidian Therapeutics (Inst)
 
Zhe Qu
Employment - SERVIER
 
Evinaa Sellaiah
Employment - SERVIER
 
Ilona Tala
Employment - SERVIER
 
Gabriel Tinoco
Consulting or Advisory Role - Deciphera; Deciphera; Deciphera; Deciphera; SynOX
 
Jonathan Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER
 
Karina Vianna
Consulting or Advisory Role - Adium Pharma; AstraZeneca; Roche/Genentech
Speakers' Bureau - AstraZeneca; Bayer; BMS Brazil; GlaxoSmithKline; Knight Pharmaceuticals; Pfizer; Roche/Genentech; SERVIER
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb Brazil (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; EP biopharma; Haihe Pharmaceutical; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
William Tap
Leadership - AstraZeneca; Atropos; Avacta Life Sciences; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Aadi; Abbisko Therapeutics; Avacta Life Sciences; Bayer; Boehringer Ingelheim; C4 Therapeutics; Curadev; Daiichi Sankyo; Deciphera; Ikena Oncology; IMGT; inhibrx; Ipsen; PharmaEssential; Ratio; Servier; Sonata
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); servier (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03